FDA reclassifies bone growth stimulators; Bioventus says 2026 guidance unchanged
The FDA has reclassified non-invasive bone growth stimulators from Class III to Class II, and new CMS billing rules for these devices will take effect on May 18, 2026. Bioventus, a company in this sector, does not anticipate these changes to materially affect its 2026 financial results and has reiterated its guidance for that year, though it will continue to monitor long-term CMS actions.
CMS reimbursement shifts leave Bioventus (NASDAQ: BVS) 2026 guidance intact
Bioventus Inc. reported that recent FDA reclassification of its Exogen Ultrasound Bone Healing System from Class III to Class II, coupled with updated CMS billing requirements and Medicare fee schedule, will not materially impact its fiscal year 2026 financial results. The company is reiterating its 2026 financial guidance but will continue to evaluate potential longer-term effects of current and future CMS actions. This update was disclosed in an 8-K filing, indicating a neutral near-term sentiment from healthcare regulatory and reimbursement analysts.
BVS SEC Filings - Bioventus Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive overview of Bioventus Inc. (BVS) SEC filings, including 10-K, 10-Q, and 8-K reports, along with insider trading forms. Recent key filings include a 10-Q quarterly report, an 8-K on a $400 million credit agreement, and an 8-K detailing FDA 510(k) clearance for two peripheral nerve stimulation devices. The platform offers AI-generated summaries, impact scoring, and sentiment analysis for each filing.
Statutory Profit Doesn't Reflect How Good Bioventus' (NASDAQ:BVS) Earnings Are
Bioventus Inc.'s recent solid earnings report might have initially underwhelmed investors, but an analysis of its accrual ratio suggests that its financial performance is stronger than statutory profits indicate. The company's free cash flow significantly exceeded its statutory profit, boasting an accrual ratio of -0.15, which is generally considered a positive sign for future profitability. This indicates a robust underlying financial health for Bioventus.
Bioventus reports Q1 revenue $132.1M, adjusted EPS $0.15 and raises cash-flow guidance
Bioventus reported strong first-quarter 2026 results with revenue of $132.1 million, a 7% increase year-over-year, and adjusted diluted earnings per Class A share of $0.15. The company's revenue growth was broad-based across its Pain Treatments, Surgical Solutions, and Restorative Therapies segments. Management also raised its full-year adjusted EPS and cash from operations guidance, while reaffirming its revenue outlook for 2026.
Bioventus (BVS) lifts 2026 EPS outlook after Q1 revenue and cash-flow gains
Bioventus reported strong first-quarter 2026 results, with revenue increasing by 7% to $132.1 million and GAAP diluted EPS turning positive at $0.04. The company significantly improved its cash from operations to $8.9 million from a previous outflow and made a $22.0 million discretionary debt prepayment. Following this performance, Bioventus raised its full-year 2026 guidance for Adjusted EPS and cash from operations while reaffirming net sales projections.
Bioventus (BVS) Q1 EPS Holds Profitability But Tests Bullish Margin Narratives
Bioventus (BVS) reported Q1 2026 revenue of US$132.1 million and basic EPS of US$0.05, maintaining profitability but sparking debate about the durability of its margins. While the company moved from losses a year ago to positive trailing EPS of US$0.43, quarterly net income declined from its Q4 2025 peak, and revenue growth forecasts remain below the broader US market. The stock trades at US$10.92, significantly below its DCF fair value, with a P/E ratio above industry averages, creating tension between its improving earnings and valuation concerns.
[10-Q] Bioventus Inc. Quarterly Earnings Report
Bioventus Inc. reported strong quarterly results, returning to profitability with net sales increasing 6.6% year-over-year to $132.1 million, driven by growth in Pain Treatments and Surgical Solutions. The company achieved a net income of $3.9 million, compared to a $3.3 million loss a year ago, and improved its gross margin to 68.7% and Adjusted EBITDA to $23.9 million. Bioventus also made a discretionary prepayment of $22.0 million on its 2025 Term Loan, signaling a positive financial position and compliance with credit covenants.
Bioventus Inc. 1Q 2026: Revenue $132.09M, EPS $0.04— 10-Q Summary
Bioventus Inc. reported strong first-quarter 2026 results, with revenue increasing to $132.09 million and diluted EPS at $0.04, a significant improvement from a net loss in the prior year. The growth was primarily driven by increased sales volumes in both U.S. and international markets, particularly in pain treatments and ultrasonics. Operational efficiencies and strategic financial actions also contributed to improved gross margin and adjusted EBITDA.
Bioventus Reports First Quarter Financial Results
Bioventus Inc. reported strong first-quarter 2026 financial results, with revenue increasing 7% to $132.1 million. The company delivered GAAP earnings of $0.04 per diluted share and non-GAAP earnings of $0.15 per diluted share, while cash from operations surged by $28.3 million. Bioventus also raised its full-year 2026 guidance for Non-GAAP EPS and Cash from Operations, driven by continued momentum across its core businesses and disciplined execution.
Bioventus (NASDAQ: BVS) sets 2026 virtual meeting, director slate and auditor vote
Bioventus Inc. (NASDAQ: BVS) has announced its 2026 virtual Annual Meeting of Stockholders to be held on June 3, 2026, at 10:00 a.m. Eastern Time. Stockholders as of April 6, 2026, will vote on the election of twelve directors and the ratification of Grant Thornton LLP as the independent auditor for 2026. The proxy statement also details the company's executive compensation, equity plans, and corporate governance practices.
Bioventus Inc. ($BVS) CEO 2025 Pay Revealed
The CEO of Bioventus Inc. ($BVS), Robert E. Claypoole, is estimated to have received $4,299,108 in compensation in 2025, a 48.38% decrease from 2024, based on a recent SEC filing. The article also details recent insider trading activity, government contracts awarded to Bioventus, significant hedge fund movements in BVS stock, and analyst price targets for the company.
Bioventus (BVS) CFO exercises 13,000 RSUs and withholds 5,648 shares for tax
Bioventus Inc.'s Senior Vice President and CFO, Mark Leonard Singleton, exercised 13,000 restricted stock units (RSUs) on April 10, 2026, receiving an equal number of Class A shares. To cover tax obligations, 5,648 Class A shares were withheld at a price of $9.06 per share in a non-market transaction. Following these transactions, Singleton directly owns 182,981 Class A shares, indicating a net increase in his equity position.
[Form 4] Bioventus Inc. Insider Trading Activity
This article reports on an insider trading activity for Bioventus Inc. (BVS) where Katrina J. Church, SVP & Chief Compliance Officer, exercised restricted stock units on April 10, 2026. She received 4,300 shares of Class A common stock and 1,868 shares were withheld to cover tax obligations. Post-transaction, her direct ownership increased to 64,164 shares, reflecting a routine equity compensation event rather than a discretionary market trade.
Bioventus (BVS) SVP gains 9,925 shares from RSU vesting, with tax withholding
Anthony D'Adamio, SVP & General Counsel of Bioventus Inc. (BVS), exercised 9,925 restricted stock units (RSUs) on April 10, 2026, converting them into 9,925 shares of Class A common stock. To cover tax obligations, 4,312 shares were disposed of at $9.06 per share through a tax-withholding transaction, not an open-market sale. Following these transactions, D'Adamio directly holds 153,655 shares of Class A common stock.
Bioventus (BVS) CFO vests 18,625 RSUs with 8,091 shares withheld for taxes
Mark Leonard Singleton, CFO of Bioventus Inc. (BVS), exercised 18,625 Restricted Stock Units (RSUs) on March 20, 2026. For tax purposes related to this vesting, 8,091 shares were withheld at a price of $8.64 per share. Following these transactions, Singleton directly holds 169,981 shares of Bioventus Class A common stock.
Bioventus (BVS) CEO adds major RSU and option grants, exercises awards
Bioventus Inc. CEO Robert E. Claypoole reported significant equity compensation changes in a recent SEC filing. On March 13, 2026, he exercised 33,500 restricted stock units, leading to 14,553 shares being withheld for tax obligations, leaving him with 135,944 Class A shares. Additionally, he received new grants of 278,000 restricted stock units and 309,000 stock options, which will vest over four years subject to his continued service.
Bioventus (BVS) CFO receives major stock awards and exercises RSUs
Bioventus Inc. CFO Mark Leonard Singleton reported significant equity compensation activities, including receiving 104,000 restricted stock units and an option for 116,000 shares on March 13, 2026. He also exercised 13,500 RSUs, with some shares withheld for tax purposes, bringing his direct holdings to 159,447 shares of Class A common stock. These awards and options are subject to a four-year vesting schedule tied to his continued service.
Bioventus (BVS) SVP granted RSUs, options and exercises prior awards
Bioventus Inc.'s Senior Vice President and Chief Compliance Officer, Katrina J. Church, received new grants of 24,000 restricted stock units and 27,000 stock options, both vesting in four annual installments starting March 15, 2026. She also exercised 6,955 previously awarded restricted stock units, with 3,022 shares withheld for tax obligations. Following these transactions, Church directly holds 61,732 shares of Class A common stock.
Bioventus (BVS) SVP & General Counsel receives RSU, option grants and exercises awards
Bioventus Inc.'s SVP and General Counsel, Anthony D'Adamio, reported new equity compensation. He received grants of 83,000 restricted stock units (RSUs) and 92,000 stock options, and also exercised 8,886 and 8,750 RSUs into Class A shares, with some shares withheld for tax obligations. Following these transactions, D'Adamio directly owned 148,042 shares of Bioventus Class A common stock.
Bioventus (BVS) director logs open-market sale of 12,000 shares
Bioventus Inc. director Michelle McMurry-Heath reported an open-market sale of 12,000 shares of Class A common stock at a weighted average price of $8.7866. The shares were sold in multiple trades ranging from $8.73 to $8.81. Following this transaction, she now directly holds 44,997 shares.
Bioventus Q4 Earnings Assessment
Bioventus (NASDAQ: BVS) announced its Q4 earnings, beating estimated EPS by 9.09% with $0.24 versus an estimate of $0.22, and revenue was up $4.26 million year-over-year. The company has a history of beating EPS estimates and provided FY 2026 guidance expecting earnings between $0.73 and $0.77 per share.
Bioventus Earnings Report: Q4 Overview
Bioventus (NASDAQ: BVS) released its Q4 earnings report, announcing an EPS of $0.24, beating the estimate of $0.22 by 9.09%. Revenue increased by $4.26 million year-over-year. The company also provided guidance for FY 2026, forecasting earnings between $0.73 and $0.77 per share.
BVS SEC Filings - Bioventus Inc. 10-K, 10-Q, 8-K Forms
This page provides a comprehensive resource for Bioventus Inc. (BVS) SEC filings, including 10-K, 10-Q, 8-K, and Form 4 documents, with AI-powered summaries. It details key financial data, financing arrangements like credit agreements, and governance changes from recent filings. The article also provides recent filings such as the Q3 2025 earnings report and FDA clearance for two new medical devices.
Preview: Bioventus's Earnings
Bioventus (NASDAQ: BVS) is scheduled to release its quarterly earnings report on Thursday, March 5, 2026, with analysts estimating an EPS of $0.22. The article provides an overview of the company's past earnings performance, stock analysis, and financial metrics, including revenue growth, net margin, return on equity, return on assets, and debt management. Bioventus is a medical technology company specializing in treatments that enhance the body's natural healing process.
Bioventus 10-K: $568.1M Revenue, $0.33 Diluted EPS
Bioventus (BVS) reported fiscal year net sales of $568.1 million, remaining flat year-over-year, and achieved net income of $27.3 million, or $0.33 diluted earnings per share. This financial performance marks a significant recovery from a loss in the previous year, driven by improved operating income, cost controls, and strategic portfolio actions. The company also saw volume growth in Pain Treatments and Surgical Solutions, along with the divestiture of its non-core Advanced Rehabilitation business.
Bioventus Announces Fourth Quarter and Full Year 2025 Financial Results
Bioventus reported strong financial results for Q4 and the full year 2025, with Q4 revenue increasing 2.8% to $157.9 million and organic revenue up 10.0%. Full-year 2025 revenue was $568.1 million, with 7.5% organic growth. The company strengthened its balance sheet, reduced debt, and provided optimistic 2026 guidance including projected net sales of $600 million to $610 million.
Bioventus Inc. to Report Fourth Quarter Fiscal Year 2025 Financial Results on March 5, 2026
Bioventus Inc. will release its Q4 fiscal year 2025 financial results on March 5, 2026, before the market opens, followed by a conference call at 8:30 a.m. Eastern Time. The company will discuss its financials and provide a business update, with a live webcast available on its investor relations website and archived for replay until March 4, 2027. The article also provides recent insider trading activity, revenue data, and institutional investor changes for BVS.
Bioventus (BVS) SVP & General Counsel exercises RSUs, withholds 6,327 shares for taxes
Anthony D'Adamio, SVP & General Counsel of Bioventus Inc. (BVS), acquired 12,980 shares of Class A common stock through the exercise of restricted stock units (RSUs) on February 15, 2026. On the same day, he disposed of 6,327 shares at $8.27 each for tax withholding purposes. Following these transactions, D'Adamio directly holds 138,069 shares of Bioventus Class A common stock.
Bioventus (BVS) SVP gets 4,375 shares, withholds 2,133 for tax
Bioventus Inc.'s SVP and Chief Compliance Officer, Katrina J. Church, exercised 4,375 restricted stock units, converting them into Class A common shares. Concurrently, 2,133 Class A shares were disposed of at $8.27 per share to cover tax obligations. Following these transactions, Church directly holds 57,799 Class A common shares and 8,750 restricted stock units.
Nantahala discloses 9.03% Bioventus (BVS) stake in Schedule 13G/A
Nantahala Capital Management, LLC, along with Wilmot B. Harkey and Daniel Mack, has reported a 9.03% beneficial ownership stake in Bioventus Inc. (BVS) Class A common stock through an amended Schedule 13G/A filing. As of December 31, 2025, they beneficially own 6,047,403 shares, holding shared voting and dispositive power. The securities were acquired and are held in the ordinary course of business, not for influencing control of Bioventus.
Bioventus Reports Second Quarter Financial Results
Bioventus has announced strong financial results for the second quarter of 2024, showing significant growth in revenue and profitability, particularly in its Pain Treatments and Surgical Solutions segments. Despite reporting a net loss due to an impairment charge and litigation costs, the company increased its adjusted EBITDA and raised its full-year financial guidance. Key strategic initiatives include the potential divestiture of its Advanced Rehabilitation Business and the FDA clearance of OSTEOAMP Cannula, aiming to enhance shareholder value and focus on core strengths.
Anderson Financial Strategies LLC Invests $901,000 in Bioventus Inc. $BVS
Anderson Financial Strategies LLC has acquired a new stake of 134,720 shares in Bioventus Inc. (NYSE:BVS) during the third quarter, valued at approximately $901,000. This investment represents about 0.16% ownership of Bioventus and constitutes roughly 0.5% of Anderson Financial Strategies LLC's portfolio. Meanwhile, two directors, Guy P. Nohra and Michelle Mcmurry-Heath, recently reduced their holdings in Bioventus through stock sales.
Recent uptick might appease Bioventus Inc. (NASDAQ:BVS) institutional owners after losing 13% over the past year
Institutional investors own 36% of Bioventus Inc. (NASDAQ:BVS), making the stock vulnerable to their trading decisions. The top 5 shareholders collectively own 52% of the company, with Essex Woodlands Management, Juniper Investment Company, and Smith & Nephew plc being the largest. Despite a 13% loss over the past year, a recent US$55m market cap gain might be welcomed by these institutional owners.
HALPER SADEH LLC ENCOURAGES BIOVENTUS INC. SHAREHOLDERS TO CONTACT THE FIRM TO DISCUSS THEIR RIGHTS
Halper Sadeh LLC, an investor rights law firm, is investigating whether officers and directors of Bioventus Inc. (NASDAQ: BVS) breached their fiduciary duties to shareholders. The firm encourages current Bioventus stockholders, especially long-term shareholders, to contact them to discuss potential legal rights and options, including seeking corporate governance reforms or financial incentives. Halper Sadeh LLC emphasizes that shareholder involvement can improve company oversight and enhance shareholder value.
Bioventus Appoints Ajay Dhankhar as New Director
Bioventus Inc. (BVS) has appointed Ajay Dhankhar, PhD, as a Class II director, effective November 14, 2025. This appointment aligns with the Stockholders Agreement, which allows Smith & Nephew affiliates to designate directors. Dr. Dhankhar will not receive compensation for his role.
Bioventus Inc. Appoints Ajay Dhankhar to Board of Directors
Bioventus Inc. announced the appointment of Ajay Dhankhar, PhD, to its Board of Directors as a Class II director, effective November 14, 2025. Dr. Dhankhar will serve until the 2026 annual meeting of stockholders and brings experience as Chief Corporate Development & Strategy Officer at Smith & Nephew plc. This appointment was officially filed with the SEC on November 17, 2025.
Bioventus appoints Ajay Dhankhar to board as Class II director
Bioventus Inc. has appointed Ajay Dhankhar, PhD, as a Class II director to its board, effective Thursday. Dr. Dhankhar, currently Chief Corporate Development & Strategy Officer at Smith & Nephew plc, will serve until the 2026 annual meeting of stockholders. This appointment aligns with a Stockholders Agreement allowing Smith & Nephew to designate directors, with Dr. Dhankhar being their second designee.
Bioventus (BVS): $17.3M One-Time Loss Raises Questions About Quality of New Profitability
Bioventus (BVS) recently returned to profitability despite a one-time loss of $17.3 million, raising questions about the quality of these new earnings. The company faces significant debt, which poses a threat to future R&D and market responsiveness. Despite trading at a steep discount to fair value, its high P/E ratio and debt burden warrant caution among investors.
BVS Stock Quote Price and Forecast
This article provides a detailed financial overview and forecast for Bioventus, Inc. (BVS), including its current stock price, recent performance, key financial metrics, and a compilation of recent news and analyst ratings. It highlights the company's operational segments and its position within the medical technology sector.
Bioventus Inc. SEC 10-Q Report
Bioventus Inc. has released its Form 10-Q report for the third quarter of 2025, highlighting stable financial performance with improvements in operating income and a positive net income turnaround. The company's U.S. segment remains the primary revenue driver, particularly in Pain Treatments and Surgical Solutions, which are also targeted for future growth alongside international expansion.
Head-To-Head Survey: Bioventus (NASDAQ:BVS) & Shoulder Innovations (NYSE:SI)
This article provides a head-to-head comparison of Bioventus (NASDAQ:BVS) and Shoulder Innovations (NYSE:SI), examining their institutional ownership, insider ownership, earnings, valuation, analyst recommendations, and profitability. The analysis concludes that Bioventus outperforms Shoulder Innovations on 7 out of 12 factors discussed. Detailed company profiles are also included.
Bioventus Secures Dual FDA Clearance for Revolutionary Non-Opioid Pain Management Technology
Bioventus (Nasdaq: BVS) has received FDA 510(k) clearances for two new peripheral nerve stimulation (PNS) products, TalisMann™ and StimTrial™, for chronic pain management. These clearances position Bioventus to tap into a PNS market projected to exceed $500 million by 2029 with over 20% annual growth. The company plans a limited commercial release in Q3 2025, followed by a broader rollout in early 2026, offering non-opioid, minimally invasive therapies.
Bioventus Announces Fourth Quarter and Full Year 2024 Financial Results
Bioventus reported strong financial results for the fourth quarter and full year 2024, with worldwide revenue increasing by 13.5% and 11.9% respectively, driven by growth in Pain Treatments and Surgical Solutions. The company also announced an increase in Adjusted EBITDA and provided optimistic financial guidance for 2025, anticipating continued revenue growth and operating margin expansion. These results follow strategic moves including the divestiture of its Advanced Rehabilitation Business and debt reduction.
Bioventus CFO Mark Leonard sells $113,018 in stock
Bioventus CFO Mark Leonard recently sold 10,733 shares of the company's Class A common stock, valued at $113,018. The company has seen its stock surge over 90% in the last six months and is expected to become profitable this year. Bioventus also reported strong third-quarter 2024 results, including a 15% year-over-year revenue increase and raised full-year guidance, highlighting its strong financial health and strategic growth initiatives.
Bioventus SVP Katrina Church sells $26,693 in stock By Investing.com
Katrina J. Church, SVP and Chief Compliance Officer at Bioventus Inc. (NASDAQ: BVS), sold 2,535 shares of company stock for $26,693 to cover taxes on vested restricted stock units. This transaction occurred after Bioventus saw a 102% gain over the past year and raised its full-year revenue guidance to between $562 million and $567 million due to strong Q3 growth. The company reported a 15% year-over-year increase in Q3 revenue to $139 million, driven by surgical solutions and the HA business.
Shareholder lawsuit ends with $15 million settlement
A federal judge has approved a $15.25 million settlement in a shareholder lawsuit against Durham-based Bioventus. The lawsuit alleged that the company misled shareholders regarding its financial performance. This settlement concludes the legal claims against the company.
Bioventus Inc. SEC 10-Q Report
Bioventus Inc. has released its Q3 2024 Form 10-Q report, detailing significant financial growth with net sales reaching $138.964 million for the quarter and $419.638 million year-to-date, marking an improvement in net loss compared to the prior year. The report highlights strategic initiatives like the divestiture of non-core assets to improve liquidity and reduce debt, new product launches, and regulatory approvals. However, the company also acknowledges challenges such as impairment charges related to divestitures, regulatory compliance costs, and potential dilution of ownership interests.
Bioventus reaches $15.25 million settlement in securities lawsuit
Bioventus Inc. has agreed to a $15.25 million settlement in a securities class action lawsuit, resolving claims related to rebate practices, financial prospects, and internal controls. While the settlement requires court approval and does not admit liability, it aims to conclude litigation dating back to January 2023. This development occurs as Bioventus reports strong financial performance in Q1 2024 and significant corporate governance changes.
Durham company agrees to $15 million settlement in shareholder lawsuit
A Durham company, Bioventus, has agreed to a $15 million settlement in a shareholder lawsuit. The lawsuit alleged that the company misstated its financial results, leading to an artificially inflated stock price. This settlement addresses claims related to these financial misrepresentations.
